From: Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients
 | n = 52 |
---|---|
Sex (male / female) | 40/12 |
Mean age (years) | 65 ± 9 |
Etiology (HBV / HCV / HBV + HCV / NBNC) | 7/29/1/15 |
Child-Pugh score (A / B / C) | 13/25/14 |
Hepatocellular carcinoma (absent / present) | 31/21 |
UICC Stage of hepatocellular carcinoma | |
 Absent (none / after curative treatment) | 19/12 |
 Present (Stage I / II / III / IV) | 8/12/0/1 |
Esophageal varices (absent / present) | 1/51 |
Monotherapy / Combination therapy | 30/22 |
White blood cell count (/μL) | 3773 ± 1994 |
Hemoglobin (g/dL) | 11.2 ± 1.8 |
Platelet count (× 104/μL) | 9.0 ± 6.4 |
Albumin (mg/dL) | 3.1 ± 0.5 |
Total bilirubin (mg/dL) | 1.6 ± 1.1 |
Aspartate aminotransferase (IU/L) | 46 ± 24 |
Alanine aminotransferase (IU/L) | 32 ± 19 |
Gamma-glutamyl transpeptidase (IU/L) | 47 ± 59 |
Prothrombin time (%) | 64 ± 14 |
Prothrombin time/International normalized ratio | 1.3 ± 0.2 |
Fibrinogen degradation product (μg/mL) | 15.7 ± 17.1 |
D-dimer (μg/mL) | 7.5 ± 8.1 |
Antithrombin III (%) | 58 ± 17 |